All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2017; the latest 2022-11-23.
From the record
Fulgent Genetics, Inc.'s filings since 2017 show 1 warning event: a notice about its exchange listing (8-K item 3.01, the latest 2022-11-23) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+42.7% a year over 9 filed years; profitable in 3 of 9.
From the record
Fulgent Genetics, Inc.'s 9 filed years say what it did: revenue went from $19 million in fiscal 2017 to $323 million in fiscal 2025, up 42.7% a year; it rose in 5 of 8 years; the deepest fall was 71% from fiscal 2021 to fiscal 2024; net income was positive in 3 of 9 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 8.9/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Fulgent Genetics, Inc.'s shareholder treatment is put at 8.9 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 11% of 24 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -5%: lost 5¢ per shareholder dollar. Leverage 8%: owes 8¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Fulgent Genetics, Inc. lost about 5 cents for every dollar of shareholders' money, and gross profitability: its products earned about 11 cents per dollar of everything the company owns. Leverage: it owed about 8 cents per dollar of assets, and net share issuance: its share count grew 1.8% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 38% of 24 in its family; net margin -18.8%.
From the record
Fulgent Genetics, Inc.'s standing among 24 graded names in its industry family: revenue of $323 million in fiscal 2025 ranks in the top 41% by size; a net margin of -18.8% ranks in the bottom 48%; revenue growth of -19.5% a year over the last 3 filed years ranks in the bottom 7% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
top 16% of 17 in its family for leadership; chief executive since 2016.
From the record
Fulgent Genetics, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Hsieh, Ming (Chief Executive Officer, as filed), filing under that title since 2016-09-28, 10.1 years (top 3% of its family); the 7 officers and directors filing in the last fifteen months have been on the record a median of 7.3 years (top 23%); 1 officer or director change was reported on Form 8-K since 2023-11-13, against the 7 people in charge now (top 20%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
bottom 42% of 24 in its family for room to expand.
From the record
Fulgent Genetics, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $50 million against no long-term debt tagged leaves 4.1% of its assets as net cash, bottom 40% of its family; cash from operations less capital spending is -38.5% of revenue (bottom 27%); a gross margin of 40.6% (top 47%); research spending of 16.7% of revenue (bottom 47%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 48% of 23 in its family for growth drivers.
From the record
Fulgent Genetics, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -19.5% a year over the last three filed years against 42.7% over all 9, slowing (bottom 7% of its family); the newest year grew 13.8% (top 50%); research spending grew 23.1% a year (top 25%); capital spending grew 6.3% a year (top 40%) (its annual reports). Fulgent Genetics, Inc. reported 2 lines of business in fiscal 2025: Laboratory Services at $322 million (100%), Therapeutic Development at $447 thousand (0%); 1 of 1 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
bottom 43% of 20 in its family for expectations against reality.
From the record
Fulgent Genetics, Inc.'s newest year against its own record: revenue of $323 million in fiscal 2025 came in 68.2% above the $192 million its prior three years' pace pointed to (top 12% of its family); net income of $61 million against a prior three-year average of $22 million (bottom 18%); a net margin of -18.8% against -16.6% before (bottom 23%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made